Allergic contact dermatitis is a common disease within the family of delayed-type hypersensitivity reactions. In more severe cases of allergic contact dermatitis, topical steroids may prove insufficient, and systemic therapeutic agents are often used. Even when systemic therapies such as cyclosporine lead to improvement, withdrawal of these agents is challenging and can lead to undesirable morbidities. Currently, there are no systemic treatments indicated for the treatment of widespread recalcitrant contact dermatitis. This review discusses the targets of in-use off-label systemic medications and potential therapeutics in the pipeline.
From the *School of Medicine, University of California, Riverside;
†Department of Dermatology, Loma Linda University, CA; and
‡Ronald O. Perelman Department of Dermatology, New York University, New York City.
Address reprint requests to Sharon E. Jacob, MD, Department of Dermatology, Loma Linda University, 11370 Anderson St, Ste 2600, Loma Linda, CA 92354. E-mail: email@example.com.
The authors have no funding or conflicts of interest to declare.